MCID: NPH010
MIFTS: 43

Nephrosclerosis malady

Categories: Rare diseases, Cardiovascular diseases, Nephrological diseases

Aliases & Classifications for Nephrosclerosis

About this section

Aliases & Descriptions for Nephrosclerosis:

Name: Nephrosclerosis 11 48 27 50 39 13 68
 
Renal Sclerosis 11

Classifications:



External Ids:

Disease Ontology11 DOID:11664
ICD1030 I12, N26.9
ICD9CM32 587
MeSH39 D009400

Summaries for Nephrosclerosis

About this section
MalaCards based summary: Nephrosclerosis, also known as renal sclerosis, is related to idiopathic panuveitis and iris disease. An important gene associated with Nephrosclerosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways are A-beta Pathways: Uptake and Degradation and Hypothesized Pathways in Pathogenesis of Cardiovascular Disease. Affiliated tissues include kidney, pituitary and heart, and related mouse phenotypes are cardiovascular system and growth/size/body region.

Related Diseases for Nephrosclerosis

About this section

Diseases related to Nephrosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 101)
idRelated DiseaseScoreTop Affiliating Genes
1idiopathic panuveitis10.2ACE, TGFB1
2iris disease10.2ACE, AGTR1
3preaxial polydactyly of fingers10.2ACE, AGTR1, TGFB1
4flat umbilicus familial10.2ACE, AGTR1, TGFB1
5systolic heart failure10.2ACE, AGTR1, TGFB1
6ulnar hemimelia10.2CTGF, SYNPO
7miliaria10.1CTGF, TGFB1
8aplasia cutis congenita recessive10.1ACE, ADRB1, AGTR1
9skin conditions10.1ACE, CCL2, TGFB1
10kartagener syndrome10.1ACE, MTHFR
11prostate neuroendocrine neoplasm10.1ACE, AGTR1, NR3C2
12eye degenerative disease10.1ACE, AGTR1, CTGF
13geleophysic dysplasia 210.1CTGF, TGFB1
14laryngostenosis10.1ACE, AGTR1, NR3C2
15acute chest syndrome10.1ACE, CCL2, TGFB1
16pars planitis10.1ACE, MTHFR
17clear cell adenocarcinoma10.1ACE, AGTR1, NR3C2
18anhidrosis10.1CTGF, TGFB1
19testicular lymphoma10.1ACE, CTGF, TGFB1
20alpha-2-plasmin inhibitor deficiency10.1ACE, AGTR1, MTHFR
21pauci-immune glomerulonephritis10.0NPHS1, NPHS2
22toxic myocarditis10.0ACE, ADRB1, NR3C2
23detrusor sphincter dyssynergia10.0ADRB1, CCL2, TGFB1
24albinism, oculocutaneous, type ia10.0CCL2, CTGF, TGFB1
25acute necrotizing encephalitis10.0CCL2, CTGF, TGFB1
26cascade stomach10.0ACE, AGTR1
27cervix small cell carcinoma10.0ACE, AGTR1, MTHFR
28malignant neoplasm of acoustic nerve10.0CCL2, CTGF, TGFB1
29sick sinus syndrome 310.0NPHS1, NPHS2
30benign secondary hypertension10.0CCL2, NPHS2, SYNPO, TGFB1
31renal tubular acidosis10.0CCL2, CTGF, TGFB1
32bullous skin disease10.0ACE, MTHFR
33glomerulonephritis10.0
34glaucoma 1, open angle, e10.0NPHS1, NPHS2
35vernal conjunctivitis10.0ACE, CTGF, MTHFR
36diprosopia10.0NPHS1, NPHS2, TGFB1
37pulmonary valve insufficiency10.0ACE, CCL2, CTGF, TGFB1
38kidney disease9.9
39hypothyroidism, congenital, nongoitrous, 39.9NPHS1, NPHS2, SYNPO
40critical limb ischemia9.9ACE, ADRB1, AGTR1, NR3C2
41congenital torticollis9.9NPHS1, NPHS2
42gastric cancer9.9NPHS1, NPHS2, SYNPO
43hypertension, essential9.9ACE, ADRB1, AGTR1, NR3C2
44focal segmental glomerulosclerosis9.9NPHS1, NPHS2
45budd-chiari syndrome9.9ACE, AGTR1, MTHFR
46hemolytic-uremic syndrome9.9
47pyrimidine metabolic disorder9.9ACE, AGTR1, CCL2, MTHFR
48macular degeneration, age-related, 129.9ACE, ADRB1, AGTR1, MTHFR
49biliary cirrhosis, primary, 29.9ACE, NPHS1, NPHS2, TGFB1
50malignant hyperthermia susceptibility 19.9ACE, NPHS1, NPHS2, SYNPO

Comorbidity relations with Nephrosclerosis via Phenotypic Disease Network (PDN):


Acute Kidney FailureChronic Kidney Failure
Deficiency AnemiaHeart Disease
Hypertension, EssentialIschemic Heart Disease
Kidney DiseaseAcute Cystitis
HydronephrosisNephrolithiasis, Type I

Graphical network of the top 20 diseases related to Nephrosclerosis:



Diseases related to nephrosclerosis

Symptoms & Phenotypes for Nephrosclerosis

About this section

MGI Mouse Phenotypes related to Nephrosclerosis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053857.9ACE, ADRB1, AGTR1, BMP5, CTGF, NPHS2
2MP:00053787.3ACE, ADRB1, AGTR1, BMP5, CTGF, MTHFR
3MP:00053677.2ACE, AGTR1, BMP5, NPHS1, NPHS2, NR3C2
4MP:00053767.1ACE, ADRB1, AGTR1, CTGF, MTHFR, NPHS1
5MP:00107686.7ACE, ADRB1, AGTR1, BMP5, CTGF, MTHFR

Drugs & Therapeutics for Nephrosclerosis

About this section

Drugs for Nephrosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Valsartanapproved, investigationalPhase 4295137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
 
Kalpress
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
2Antihypertensive AgentsPhase 4, Phase 2, Phase 34207
3Angiotensin II Type 1 Receptor BlockersPhase 41091
4
Angiotensin IIPhase 4117868521-88-0, 11128-99-765143, 172198
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
5Angiotensin Receptor AntagonistsPhase 41191
6AngiotensinogenPhase 41177
7
EpoprostenolapprovedPhase 2, Phase 35461849-14-7, 35121-78-95280427, 5282411
Synonyms:
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E)-(15S)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13e)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oate
(5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oate
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13e,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
136626-78-3
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
61849-14-7
63748-50-5
63859-31-4
AC1L18LX
AC1L3FZB
AC1NQX0K
AC1NR00P
AC1O51WG
AC1O5HI7
AR-1I7150
BIDD:GT0514
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
Bio2_000216
Bio2_000696
C01312
CHEBI:15552
CHEMBL1139
CHEMBL307845
CID114805
CID11969614
CID159
CID5280427
CID5282411
CID6434194
CID6450541
 
CID9864371
CID9975312
D00106
DB01240
Epoprostanol
Epoprostenol
Epoprostenol (TN)
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
HMS1791K18
HMS1989K18
IDI1_033966
KB-IV-24
KBio2_000216
KBio2_002784
KBio2_005352
KBio3_000431
KBio3_000432
KBioGR_000216
KBioSS_000216
LMFA03010087
LS-125828
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PDSP1_001721
PDSP2_001704
PG-I2
PGI(sub 2)
PGI2
PGX
Prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin I
Prostaglandin I(2)
Prostaglandin I2
Prostaglandin X
Prostaglandin x
Prostaglandins X
SMP2_000227
TRY 200
Try-200
U 53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
epoprostenol
prostacyclin
prostaglandin I2
8BeraprostinvestigationalPhase 2, Phase 31688430-50-6
9Vasodilator AgentsPhase 2, Phase 33543
10Platelet Aggregation InhibitorsPhase 2, Phase 32516
11TezosentanPhase 2, Phase 364

Interventional clinical trials:

idNameStatusNCT IDPhase
1Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseTerminatedNCT01129557Phase 4
2TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)CompletedNCT01090037Phase 2, Phase 3
3TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)CompletedNCT02480751Phase 2
4Renal NCE-MRI in Healthy VolunteersCompletedNCT02618460

Search NIH Clinical Center for Nephrosclerosis


Cochrane evidence based reviews: nephrosclerosis

Genetic Tests for Nephrosclerosis

About this section

Genetic tests related to Nephrosclerosis:

id Genetic test Affiliating Genes
1 Nephrosclerosis27

Anatomical Context for Nephrosclerosis

About this section

MalaCards organs/tissues related to Nephrosclerosis:

36
Kidney, Pituitary, Heart, Pancreas, Bone, Smooth muscle, Endothelial

Publications for Nephrosclerosis

About this section

Articles related to Nephrosclerosis:

(show top 50)    (show all 268)
idTitleAuthorsYear
1
Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study. (27066888)
2016
2
Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis. (26809068)
2016
3
Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. (26839894)
2016
4
Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. (26857648)
2016
5
Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. (27784849)
2016
6
Curcumin ameliorates nephrosclerosis via suppression of histone acetylation independent of hypertension. (27190365)
2016
7
Malignant nephrosclerosis in a patient with familial Mediterranean fever. (26466703)
2015
8
Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years' experience in a single, kidney disease center. (25838316)
2015
9
The Renal Protective Effect of Jiangya Tongluo Formula, through Regulation of Adrenomedullin and Angiotensin II, in Rats with Hypertensive Nephrosclerosis. (26557147)
2015
10
Nephrosclerosis: A Term in Quest of a Disease. (25871843)
2015
11
Glomerular Density in Biopsy-Proven Hypertensive Nephrosclerosis. (25631380)
2015
12
A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. (25233856)
2014
13
Nephrosclerosis: update on a centenarian. (25488894)
2014
14
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model. (24958497)
2014
15
Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine. (23902971)
2013
16
Effect of intensive blood pressure control on cardiovascular remodeling in hypertensive patients with nephrosclerosis. (24102027)
2013
17
Hypertensive nephrosclerosis: not enough of a good thing? (23283991)
2013
18
Subclinical nephrosclerosis is linked to left ventricular hypertrophy independent of classical atherogenic factors. (24305517)
2013
19
Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. (23832327)
2013
20
Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis. (23151750)
2013
21
Castleman's disease accompanied by hypolipidemic cerebral hemorrhage and nephrosclerosis. (23857095)
2013
22
Endothelial Sirtuin 1 Deficiency Perpetrates Nephrosclerosis through Downregulation of Matrix Metalloproteinase-14: Relevance to Fibrosis of Vascular Senescence. (24136919)
2013
23
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis. (23135868)
2013
24
Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race. (24327566)
2013
25
Association of hypoalbuminemia with severe anemia in patients with diabetic nephrosclerosis. (22236281)
2012
26
Arteriolar vascular smooth muscle cell differentiation in benign nephrosclerosis. (22319217)
2012
27
Need for education on the differential diagnosis between chronic glomerulonephritis and nephrosclerosis, and treatment of both conditions to reduce the number of patients requiring hemodialysis in Wakayama. (22821095)
2012
28
ADAMTS13--marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis. (20923926)
2011
29
The role of bone morphogenetic protein-5 (BMP-5) in human nephrosclerosis. (21319131)
2011
30
Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. (21346373)
2011
31
Involvement of connective tissue growth factor in human and experimental hypertensive nephrosclerosis. (20689330)
2011
32
Nephrosclerosis and carotid atherosclerosis: lessons from kidney donor histology. (21777346)
2011
33
Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging? (21832860)
2011
34
Hypertensive nephrosclerosis in Kenya. (22179094)
2011
35
Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. (20801567)
2010
36
Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. (20484896)
2010
37
Human nephrosclerosis triggers a hypoxia-related glomerulopathy. (20019191)
2010
38
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. (20651163)
2010
39
The association between age and nephrosclerosis on renal biopsy among healthy adults. (20439574)
2010
40
Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. (19910931)
2010
41
Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. (21080950)
2010
42
Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]. (19799194)
2009
43
Renal dysplasia and nephrosclerosis in calves. (19933543)
2009
44
Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. (19745105)
2009
45
Podocyte loss in human hypertensive nephrosclerosis. (19131934)
2009
46
(Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. (18212268)
2008
47
Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. (18698220)
2008
48
Hypertensive nephrosclerosis. (18408477)
2008
49
Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. (17414670)
2007
50
Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. (17785932)
2007

Variations for Nephrosclerosis

About this section

Expression for genes affiliated with Nephrosclerosis

About this section
Search GEO for disease gene expression data for Nephrosclerosis.

Pathways for genes affiliated with Nephrosclerosis

About this section

GO Terms for genes affiliated with Nephrosclerosis

About this section

Cellular components related to Nephrosclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1slit diaphragmGO:00360579.6NPHS1, NPHS2

Biological processes related to Nephrosclerosis according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1mononuclear cell proliferationGO:003294310.6ACE, TGFB1
2positive regulation of cellular protein metabolic processGO:003227010.6AGTR1, TGFB1
3regulation of blood vessel diameterGO:009774610.5ACE, AGTR1
4regulation of systemic arterial blood pressure by renin-angiotensinGO:000308110.5ACE, AGTR1
5regulation of vasoconstrictionGO:001922910.5ACE, AGTR1
6regulation of vasodilationGO:004231210.5ACE, AGTR1
7cellular response to dexamethasone stimulusGO:007154910.4CCL2, TGFB1
8lipopolysaccharide-mediated signaling pathwayGO:003166310.4CCL2, TGFB1
9protein kinase B signalingGO:004349110.4CCL2, TGFB1
10agingGO:00075689.9CCL2, CTGF, TGFB1
11positive regulation of collagen biosynthetic processGO:00329679.9CCL2, CTGF, TGFB1
12positive regulation of ERK1 and ERK2 cascadeGO:00703749.9CCL2, CTGF, TGFB1
13response to hypoxiaGO:00016669.6CCL2, MTHFR, TGFB1
14response to amino acidGO:00432009.5CCL2, CTGF, MTHFR
15response to woundingGO:00096119.2CCL2, CTGF, TGFB1

Molecular functions related to Nephrosclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1bradykinin receptor bindingGO:003171110.5ACE, AGTR1
2growth factor activityGO:00080839.3BMP5, CTGF, TGFB1

Sources for Nephrosclerosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet